ARCHIMED is a global private equity firm dedicated exclusively to healthcare industries, founded in 2014 with a singular mission: to accelerate the development of healthcare solutions that benefit patients worldwide. The firm focuses on small-cap and mid-cap growth buyout transactions across eight targeted healthcare sectors - Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, Pharma Services, and Animal & Environmental Health. What sets ARCHIMED apart is its integrated approach combining operational, medical, scientific, and financial expertise, allowing the firm to serve as both a strategic and financial partner to healthcare businesses across Europe, North America, and Asia.
With over 200 team members representing 35+ nationalities, ARCHIMED manages €8 billion across its funds and has invested in more than 80 companies representing over €50 billion in combined value. The firm's strategy is built on a proprietary market segmentation called MedSeg, which splits healthcare industries into 400+ sub-sectors that are individually assessed and prioritized. ARCHIMED's transatlantic platform supports portfolio companies through internationalization, innovation, M&A, and operational excellence. The firm delivers superior returns to investors - all ARCHIMED funds rank as top-decile performers - while maintaining a strong commitment to impact investing through its EURÊKA Foundation, which returns 5% of carried interest profits to the community.